TNFRSF17 and Miyoshi myopathy: Indeed, some patients relapsed with BCMA+ MM cells, while circulating anti-BCMA CAR T cells were still being detected, suggesting that CAR T-cell persistence and antigen expression on target cells may be necessary but not sufficient to exert long-lasting antitumor immunity [161].